keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer early diagnosis

keyword
https://www.readbyqxmd.com/read/29156299/outcomes-from-ovarian-cancer-screening-in-the-plco-trial-histologic-heterogeneity-impacts-detection-overdiagnosis-and-survival
#1
Sarah M Temkin, Eric A Miller, Goli Samimi, Christine D Berg, Paul Pinsky, Lori Minasian
AIM: A mortality benefit from screening for ovarian cancer has never been demonstrated. The aim of this study was to evaluate the screening outcomes for different histologic subtypes of ovarian cancers. METHODS: Women in the screening arm of the Prostate, Lung, Colorectal and Ovarian Screening Trial underwent CA-125 and transvaginal ultrasound annually for 3-5 years. We compared screening test characteristics (including overdiagnosis) and outcomes by tumour type (type II versus other) and study arm (screening versus usual care)...
November 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29141850/autoantibodies-against-hsf1-and-ccdc155-as-biomarkers-of-early-stage-high-grade-serous-ovarian-cancer
#2
Amy L Wilson, Laura R Moffitt, Nadine Duffield, Adam Rainczuk, Tom W Jobling, Magdalena Plebanski, Andrew N Stephens
BACKGROUND: Tumor-directed circulating autoantibodies (AAbs) are a well-established feature of many solid tumor types, and are often observed prior to clinical disease manifestation. As such, they may provide a good indicator of early disease development. We have conducted a pilot study to identify novel AAbs as markers of early stage HGSOCs. METHODS: A rare cohort of patients with early (FIGO stage Ia-c) HGSOCs for IgG, IgA and IgM-mediated AAb reactivity using high content protein arrays (containing 9184 individual proteins)...
November 15, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29132396/circulating-cell-free-dna-and-circulating-tumor-cells-the-liquid-biopsies-in-ovarian-cancer
#3
REVIEW
Xianliang Cheng, Lei Zhang, Yajuan Chen, Chen Qing
Limited understanding of ovarian cancer (OC) genome portrait has hindered the therapeutic advances. The serial monitoring of tumor genotypes is becoming increasingly attainable with circulating cell-free DNA (cf-DNA) and circulating tumor cells (CTCs) emerging as "liquid biopsies". They represent non-invasive biomarkers and are viable, as they can be isolated from human plasma, serum and other body fluids. Molecular characterization of circulating tumor DNA (ct-DNA) and CTCs offer unique potentials to better understand the biology of metastasis and resistance to therapies...
November 13, 2017: Journal of Ovarian Research
https://www.readbyqxmd.com/read/29131023/evaluation-of-serum-nidogen-2-as-a-screening-and-diagnostic-tool-for-ovarian-cancer
#4
Haitham A Torky, Ahmed Sherif, Ashraf Abo-Louz, Mohamed Ali, Ali Ahmed, Ahmad Ali
INTRODUCTION: Ovarian cancer is a relatively common occurrence with the formation of a tumour in the ovaries and is the leading cause of death in the gynecological field. Despite enormous efforts, there are no successful screening methods developed until now to decrease mortality in this regard. AIM: To evaluate nidogen-2 as a new tumour marker combined with higher sensitivity, specificity and accuracy than carbohydrate antigen (CA-125) and Doppler ultrasound to improve early diagnosis of ovarian cancer...
November 7, 2017: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/29125478/utility-of-paraneoplastic-antigens-as-biomarkers-for-surveillance-and-prediction-of-recurrence-in-ovarian-cancer
#5
Madhumita Chatterjee, Laura C Hurley, Nancy K Levin, Matthew Stack, Michael A Tainsky
BACKGROUND: Ovarian cancer is frequently diagnosed at an advanced stage and 70% of patients experience recurrence months to years from initial diagnosis. The expression of paraneoplastic antigens can result in the occurrence of onconeural autoantibodies in ovarian cancer that may be associated with neurological disorders that are clinically manifested in patients before diagnosis of ovarian cancer. These paraneoplastic antigens can serve as excellent biomarkers not only for early detection but also for monitoring ovarian cancer recurrence...
November 3, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29117576/the-utility-of-anti-m%C3%A3-llerian-hormone-in-the-diagnosis-and-prediction-of-loss-of-ovarian-function-following-chemotherapy-for-early-breast-cancer
#6
R A Anderson, J Mansi, R E Coleman, D J A Adamson, R C F Leonard
AIM: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy. METHODS: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed...
November 5, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29100380/circulating-tumor-cells-in-the-differential-diagnosis-of-adnexal-masses
#7
Dong Hoon Suh, Miseon Kim, Jin Young Choi, Jiyoon Bu, Yoon-Tae Kang, Byung Su Kwon, Banghyun Lee, Kidong Kim, Jae Hong No, Yong-Beom Kim, Young-Ho Cho
The aim of this study was to evaluate circulating tumor cell (CTC) detection in the differential diagnosis of adnexal masses. A total of 87 preoperative women with an indeterminate adnexal mass were prospectively enrolled. Preoperative diagnostic modalities including CTC detection, risk of ovarian malignancy algorithm, risk of malignancy index, and computed tomography or magnetic resonance imaging were compared. Forty-three (49.4%) benign tumors, 13 (14.9%) borderline malignant masses, and 31 (35.7%) cancers were pathologically confirmed...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29071831/-screening-in-onco-gynecology-beneficial-for-all-patients
#8
Lorraine Grangier, Patrick Petignat, Manuela Undurraga Malinverno
Every day, 5 women are diagnosed with gynecological cancer in Switzerland. Prognosis of ovarian, endometrial and cervical cancer is dependent on early diagnosis. Cervical cancer mortality has decreased since the introduction of screening. Unfortunately, screening in ovarian and endometrial cancer has not shown the same results. On the contrary, patients screened for these cancers have an increased morbidity without any additional benefit of survival. This article presents a review of the clinical benefits and harms of gynecological cancer screening...
October 25, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29069951/familial-swyer-syndrome-a-rare-genetic-entity
#9
Manilal Banoth, Ramana Reddy Naru, Mohammed Basheeruddin Inamdar, Amit Kumar Chowhan
Swyer syndrome is a pure gonadal dysgenesis associated with a 46 XY karyotype and primary amenorrhea in a phenotypic female. Individuals in this syndrome are at an increased risk for development of gonadal malignancies. Swyer syndrome (gonadal dysgenesis) running in families is rare event and few such scenarios were reported in the literature. Here we are presenting this rare entity involving three affected siblings born to a non-consanguineous couple. Index case - A 23-year-old female with primary amenorrhea is presented with a mass per abdomen...
October 26, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29036787/evaluation-of-serum-ccl18-as-a-potential-biomarker-for-ovarian-cancer
#10
Linjing Yuan, Jianxin Wan, Chumei Huang, Jingjing Liang, Min Liu, Caifeng Yue, Laisheng Li
BACKGROUND: Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may correlate with cancer patients' prognosis. OBJECTIVE: We performed this study to investigate the relationship between CCL18 levels and clinical characteristics of EOC patients, and to explore their diagnostic and prognostic values...
September 29, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29028099/the-diagnostic-value-of-determination-of-serum-golph3-associated-with-ca125-ca19-9-in-patients-with-ovarian-cancer
#11
H-Y Fan, D-M Duan, Y-F Liu
OBJECTIVE: To evaluate the value of three tumor markers serum Golgi phosphoprotein-3 (GOLPH3), cancer antigen 125 (CA125) and cancer antigen 19-9 (CA19.9) in the diagnosis and postoperative evaluation of ovarian cancer by detecting these three markers. PATIENTS AND METHODS: A total of 187 patients were studied and included in the ovarian cancer group, benign pelvic mass group, and the normal control group. The levels of serum Golgi phosphoprotein-3 (GOLPH3), cancer antigen 125 (CA125) and cancer antigen 199 (CA19...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28991298/exosomal-delivery-of-berry-anthocyanidins-for-the-management-of-ovarian-cancer
#12
Farrukh Aqil, Jeyaprakash Jeyabalan, Ashish K Agrawal, Al-Hassan Kyakulaga, Radha Munagala, Lynn Parker, Ramesh C Gupta
Despite optimal diagnosis and early therapeutic interventions, the prognosis for ovarian cancer patients remains dismal because the efficacy of chemotherapy is limited by the development of resistance and off-site toxicity. Berry bioactives indicate preventive and therapeutic activities against various cancer types. Here, we examined the antiproliferative activity of berry anthocyanidins (Anthos) against drug-sensitive (A2780) and drug-resistant (A2780/CP70, OVCA432 and OVCA433) ovarian cancer cells. These drug-resistant ovarian cancer cell lines overexpress p-glycoproteins (PgP) and show >100-fold resistance to the chemotherapeutic drug cisplatin compared to A2780...
October 9, 2017: Food & Function
https://www.readbyqxmd.com/read/28969237/evaluation-of-iota-simple-ultrasound-rules-to-distinguish-benign-and-malignant-ovarian-tumours
#13
Sugandha Garg, Amarjit Kaur, Jaswinder Kaur Mohi, Preet Kanwal Sibia, Navkiran Kaur
INTRODUCTION: IOTA stands for International Ovarian Tumour Analysis group. Ovarian cancer is one of the common cancers in women and is diagnosed at later stage in majority. The limiting factor for early diagnosis is lack of standardized terms and procedures in gynaecological sonography. Introduction of IOTA rules has provided some consistency in defining morphological features of ovarian masses through a standardized examination technique. AIM: To evaluate the efficacy of IOTA simple ultrasound rules in distinguishing benign and malignant ovarian tumours and establishing their use as a tool in early diagnosis of ovarian malignancy...
August 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28936272/hereditary-gynaecologic-cancers-in-nepal-a-proposed-model-of-care-to-serve-high-risk-populations-in-developing-countries
#14
Hanoon P Pokharel, Neville F Hacker, Lesley Andrews
BACKGROUND: Endometrial, ovarian and breast cancers are paradigms for global health disparity. Women living in the developing world continue to present in later stages of disease and have fewer options for treatment than those in developed countries. Risk reducing surgery is of proven benefit for women at high risk of gynaecological cancer. There is no specific model for identification and management of such women in the developing world. METHODS: We have integrated data from our published audit of a major gynaecological oncology centre at Royal Hospital for Women in Australia, with data from our survey and a focus group discussion of Nepalese gynaecological health care professionals regarding genetic testing, and findings from the literature...
2017: Hereditary Cancer in Clinical Practice
https://www.readbyqxmd.com/read/28930804/venous-thromboembolism-in-gynecological-malignancy
#15
Abigail Cohen, Chung Sim Lim, Alun Huw Davies
OBJECTIVE: Venous thromboembolism (VTE) is a recognized complication of gynecological malignancy and represents a leading cause of morbidity and mortality in these patients. The review aimed to discuss the incidence, risk factors, and clinical presentation of VTE before examining the literature on the diagnosis, prevention, and management in the context of uterine, cervical, ovarian, and vulval cancers. METHODS/MATERIALS: A literature search was performed using Ovid Medline and Embase with the following words: "gynecological malignancy," "pelvic tumor," "venous thromboembolism," "deep vein thrombosis" and "pulmonary embolism...
November 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28928083/preparation-and-characterization-of-a-high-affinity-monoclonal-antibody-against-human-epididymis-protein-4
#16
Yunlong Shen, Yuxi Wang, Xiaohua Jiang, Liang Lu, Chengdi Wang, Wenxin Luo, Yongxia Zhang, Pei Li, Zhengwei Du, Tengfei Dai, Congcong Wu, Aiping Fang, Yuqin Yao, Qian Peng, Jinliang Yang
Human epididymis protein-4 (HE4) may serve as a putative biomarker for the early diagnosis, therapy and especially prognosis of ovarian, lung and breast cancer. Detection and targeting of HE4 using the anti-HE4 antibody could be one of the effective strategies for the cancer diagnosis and treatment in clinical practice. In this study, a high-efficiency expression system was established to purify recombinant HE4. We obtained high purity HE4 in 400 mg quantity from 1 L culture supernatant of HEK293F cells. CCK-8 and cell cycle assays indicated that the purified recombinant HE4 protein could promote SKOV3 cell cycle and proliferation at the concentration of 0...
January 2018: Protein Expression and Purification
https://www.readbyqxmd.com/read/28922388/expression-and-prognosis-analyses-of-the-tob-btg-antiproliferative-apro-protein-family-in-human-cancers
#17
Yuru Bai, Lu Qiao, Ning Xie, Yongquan Shi, Na Liu, Jinhai Wang
BACKGROUND: Despite advances in early diagnosis and treatment, cancer remains the major cause of mortality in the world. The Tob/BTG antiproliferative (APRO) protein family is reported to participate in diverse human diseases. However, there's little known about their expression and prognostic values in most human cancers. METHODS: We performed a detailed cancer vs. normal analysis. The mRNA expression levels of APRO family in various cancers were analyzed via the Oncomine database...
2017: PloS One
https://www.readbyqxmd.com/read/28919321/clinicopathological-pattern-and-outcome-of-pediatric-malignant-ovarian-germ-cell-tumors-south-egypt-cancer-institute-experience
#18
Amany Ali, Heba Sayed, Mohamed Salem, Mohamed Hamdy, Amro Farok
BACKGROUND: Malignant ovarian germ cell tumors (MOGCTs) are rare and represent 1-1.5% of all cancers in children and adolescents. The aim of this study is to analyze the clinicopathological pattern at presentation and management and outcome of MOGCTs in children and adolescents. PATIENTS AND METHODS: Retrospective study included all girls diagnosed with MOGCTs between January 2005 and January 2015 in Pediatric and Surgical Oncology Departments at South Egypt Cancer Institute, Assiut University...
September 1, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/28911092/concurrent-and-sequential-initiation-of-ovarian-function-suppression-with-chemotherapy-in-premenopausal-women-with-endocrine-responsive-early-breast-cancer-an-exploratory-analysis-of-text-and-soft
#19
M M Regan, B A Walley, P A Francis, G F Fleming, I Láng, H L Gómez, M Colleoni, C Tondini, G Pinotti, M Salim, S Spazzapan, V Parmar, T Ruhstaller, E A Abdi, R D Gelber, A S Coates, A Goldhirsch, O Pagani
Background: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation. Design and methods: We analyzed 1872 patients enrolled in the randomized phase III TEXT and SOFT trials who received adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer and upon randomization to an OFS-containing adjuvant endocrine therapy, initiated gonadotropin-releasing-hormone-agonist triptorelin...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28904856/mir-101-inhibits-ovarian-carcinogenesis-by-repressing-the-expression-of-brain-derived-neurotrophic-factor
#20
Ying Xu, Lei Xu, Jianbin Zheng, Lei Geng, Shuping Zhao
Ovarian cancer is one of the most lethal malignant gynecological tumors as a result of difficulties in early-stage detection and a lack of effective treatments for patients with advanced or recurrent cancer. In the present study, we aimed to explore whether some of the microRNA (miRNA) content of serum might be related to ovarian cancer, as well as the role of these miRNAs and their intercellular transport via exosomes in ovarian cancer. We first detected the expression of six candidate miRNAs in ovarian cancer tissues and adjacent nontumor ovarian samples from 36 patients and confirmed the altered expression of four miRNAs...
September 2017: FEBS Open Bio
keyword
keyword
86585
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"